Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ages 18 to 75 years inclusive~* Ischemic symptoms lasting \>= 5 minutes at rest within the prior 48 hours~* Able to be randomized within 48 hours of recent ischemic events~* At least one of the following criteria (A, B, or C): A. Elevation of CK-MB or troponin above upper limit of normal OR B. ST segment deviation (depression or transient elevation) of at least 0.5 mm OR C. TIMI risk score \>= 3, defined as three or more of the following:~  * Age \>= 65;~ * At least 3 of the following risk factors: hypertension, diabetes mellitus, current smoker (within 1 year), dyslipidemia, family history of premature coronary artery disease (\< age 60);~ * Known or prior coronary artery stenosis \> 50%;~ * Daily aspirin use for at least 7 days;~ * \>= 2 ischemic episodes at rest lasting \>= 15 minutes each within the prior 24 hours;~ * Elevation of CK-MB OR troponin above upper limit of normal;~ * ST segment deviation (depression or transient elevation) of at least 0.5 mm.~* Ability to understand and willingness to give written informed consent~* Planned early invasive strategy in the index hospitalization~Exclusion Criteria:~* Index event is ST-segment elevation MI or new LBBB~* CABG is planned within 7 days~* ACS is secondary to non-atherosclerotic mechanism (e.g. thyrotoxicosis, anemia)~* Prior participation in ANTHEM-TIMI 32, prior exposure to rNAPc2, or participation in a study with any experimental drug or device within 30 days~* Pregnancy, lactation or use of an intrauterine device (note: women of childbearing potential must have a negative b-HCG)~* Active renal disease, Cr \> 4 mg/dl, or history of renal transplantation~* History of a bleeding diathesis or recurrent bleeding episodes~* Medical comorbidities which place subject at risk for hemorrhage, including, but not limited to, prior cerebral hemorrhage, arteriovenous malformation, non-hemorrhagic CVA or TIA, GI bleed, active PUD, advanced liver or renal disease. Major trauma, surgery, CNS, spinal or eye surgery within 6 months, or parenchymal organ biopsy within 14 days.~* Uncontrolled hypertension (SBP \> 180, DBP \> 100) despite 1 hour of adequate treatment~* Gross hematuria within 1 month unless catheterized and subsequently resolved~* Chronic warfarin (INR \> 1.4) or anticipated therapy for warfarin~* Platelet count \< 120,000/mm3 at randomization or history of thrombocytopenia (confirm in a blue-top tube using sodium citrate)~* Significant anemia (M: Hg \< 11 g/dL, F: Hg \< 10 g/dL) at randomization~* Active liver disease or ALT and AST \> 3 x ULN not felt to be part of presenting ACS~* Fibrinolytic agent within 24 hours or planned use of fibrinolytics~* Known allergy or intolerance to aspirin~* Known allergy to heparin, enoxaparin or pork-based products~* History of heparin-induced thrombocytopenia (type 1 or 2)~* Any condition for which the investigator feels enrollment in the study would place the subject at unacceptable risk (e.g. substance abuse)~* Part 2 ONLY: Use of LMWH or Xa inhibitor (e.g. Angiomax, Argatroban) \>= 12 hours before randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).